2025 Targeted Therapies of Lung Cancer (TTLC) - Posters-PP01.48 Contemporary analysis of adjuvant treatment patterns in patients with resected NSCLC in the US

Pdf Summary

The document provides an analysis of adjuvant treatment patterns for non-small cell lung cancer (NSCLC) in the United States following the regulatory approval of pembrolizumab use in January 2023. This retrospective observational study aims to explore real-world patterns of immune checkpoint inhibitor (ICI) use in conjunction with adjuvant chemotherapy for patients with resected NSCLC. Data was collected from the Flatiron Health database, comprising information from 280 cancer clinics across the US. The study included 262 patients with resectable stage II-IIIB(N2) NSCLC who underwent resection between January 2023 and March 2024.<br /><br />Key findings reveal that a significant majority (84%) of these patients received adjuvant platinum-based chemotherapy post-surgery, yet only 51% proceeded to receive subsequent ICI therapy, despite it being part of the current standard of care. Analysis indicates that factors such as smoking history and PD-L1 expression levels influenced whether patients received combined chemotherapy and ICI. However, there were no significant differences in ICI therapy administration based on pathologic staging.<br /><br />The findings suggest gaps in the implementation of recommended treatment practices. The study notes potential limitations due to the use of univariate tests for comparing cohorts, which do not account for potential confounders, and the relatively short patient follow-up period aimed at assessing recent treatment trends.<br /><br />The authors conclude that there is a need for further, more extensive studies with prolonged follow-up to better personalize systemic therapy in resectable NSCLC, particularly regarding the role of ICIs following chemotherapy. The research was funded by Merck & Co., and results were presented at the TTLC conference in February 2025. The document acknowledges contributions from several researchers and disclosures regarding their affiliations with pharmaceutical companies.

Asset Subtitle

Grace Ha

Keywords

NSCLC

adjuvant treatment

pembrolizumab

immune checkpoint inhibitor

Flatiron Health database

platinum-based chemotherapy

PD-L1 expression

treatment gaps

Merck & Co.

TTLC conference